A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophageal Cancer, FAST-GO Study

Open to people ages 18 years and up

• • Adults ≥ 18 years old at the start of study treatment.
    • New diagnosis of early-stage (Stage I, II, III) esophageal, gastroesophageal junction, or gastric adenocarcinoma, squamous cell carcinoma, or poorly differentiated carcinoma.
    • Plan to start systemic therapy for resectable or potentially resectable disease.
    • Ability to understand and the willingness to sign a written informed consent document.

• • Patients with stage I disease with plans to undergo endoscopic resection or surgery alone without perioperative systemic therapy.
    • Metastatic disease at the time of diagnosis.
    • Patients who are unable to provide informed consent.
    • Any condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures.
    • Currently participating in another intervention research study seeking to improve functional status, alleviate frailty, increase muscle strength, or improve cognitive function.